- Home
- CLLS vs SABA Comparison
CLLS vs SABA Comparison
Compare CLLS & SABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLLS
- SABA
- Stock Information
- Founded
- CLLS 1999
- SABA 1988
- Country
- CLLS France
- SABA United States
- Employees
- CLLS N/A
- SABA N/A
- Industry
- CLLS Biotechnology: Pharmaceutical Preparations
- SABA
- Sector
- CLLS Health Care
- SABA
- Exchange
- CLLS Nasdaq
- SABA Nasdaq
- Market Cap
- CLLS 299.0M
- SABA 257.3M
- IPO Year
- CLLS 2007
- SABA N/A
- Fundamental
- Price
- CLLS $3.03
- SABA $9.16
- Analyst Decision
- CLLS Buy
- SABA
- Analyst Count
- CLLS 1
- SABA 0
- Target Price
- CLLS $4.00
- SABA N/A
- AVG Volume (30 Days)
- CLLS 79.8K
- SABA 290.0K
- Earning Date
- CLLS 11-03-2025
- SABA 01-01-0001
- Dividend Yield
- CLLS N/A
- SABA 12.91%
- EPS Growth
- CLLS N/A
- SABA N/A
- EPS
- CLLS N/A
- SABA N/A
- Revenue
- CLLS $63,438,000.00
- SABA N/A
- Revenue This Year
- CLLS N/A
- SABA N/A
- Revenue Next Year
- CLLS $66.76
- SABA N/A
- P/E Ratio
- CLLS N/A
- SABA N/A
- Revenue Growth
- CLLS 223.09
- SABA N/A
- 52 Week Low
- CLLS $1.10
- SABA $3.64
- 52 Week High
- CLLS $3.35
- SABA $4.42
- Technical
- Relative Strength Index (RSI)
- CLLS 62.60
- SABA 44.09
- Support Level
- CLLS $2.88
- SABA $9.13
- Resistance Level
- CLLS $3.35
- SABA $9.23
- Average True Range (ATR)
- CLLS 0.17
- SABA 0.09
- MACD
- CLLS 0.02
- SABA -0.01
- Stochastic Oscillator
- CLLS 62.38
- SABA 15.70
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
About SABA Saba Capital Income & Opportunities Fund II Shares of Beneficial Interest
Saba Capital Income & Opportunities Fund II is a closed-end fund. The company seeks high current income, with a secondary goal of capital appreciation. The fund invests in fixed income markets across the globe.